Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2181 to 2190 of 2581 total matches.

Menactra: A Meningococcal Conjugate Vaccine

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2005  (Issue 1206)
Letter ® On Drugs and Therapeutics IN THIS ISSUE Menactra: A Meningococcal Conjugate Vaccine Volume ...
The FDA has approved a conjugated polysaccharide vaccine, Menactra (Sanofi-Pasteur), for protection against disease caused by Neisseria meningitidis in people 11-55 years old, and the manufacturer has applied for approval for use in children 2 to 10 years old. An unconjugated meningoccocal polysaccharide vaccine (Menomune - Sanofi-Pasteur) has been licensed in the US since 1981.
Med Lett Drugs Ther. 2005 Apr 11;47(1206):29-31 |  Show IntroductionHide Introduction

Adacel and Boostrix: Tdap Vaccines for Adolescents and Adults

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006  (Issue 1226)
Letter ® On Drugs and Therapeutics IN THIS ISSUE Volume 48 (Issue 1226) January 16, 2006 ...
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine...
Med Lett Drugs Ther. 2006 Jan 16;48(1226):5-6 |  Show IntroductionHide Introduction

H1N1 Vaccine for Prevention of Pandemic Influenza

   
The Medical Letter on Drugs and Therapeutics • Oct 05, 2009  (Issue 1322)
The Medical Letter ® On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 ...
The FDA has licensed 4 new monovalent vaccines for prevention of respiratory illness caused by a new influenza A H1N1 virus that appears to be derived from a swine strain. The 5th vaccine should be licensed soon. All of these vaccines are expected to become available in October. An intranasal formulation is expected in the first week of October.
Med Lett Drugs Ther. 2009 Oct 5;51(1322):77-8 |  Show IntroductionHide Introduction

Mercury in Fish

   
The Medical Letter on Drugs and Therapeutics • Dec 14, 2009  (Issue 1327)
The Medical Letter ® On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 ...
Recent news articles about mercury in fish may lead some patients to seek more information from their healthcare providers. For most Americans, seafood is the major source of exposure to mercury. The mercury in seafood is in the form of methylmercury, a potential neurotoxin formed by the organification of elemental mercury by marine microorganisms like plankton, which are then consumed by aquatic animals and concentrated up the food chain.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):103-4 |  Show IntroductionHide Introduction

A New Conjugate Meningococcal Vaccine (Menveo)

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2010  (Issue 1343)
The Medical Letter ® On Drugs and Therapeutics Published by The Medical Letter, Inc. • 145 ...
The FDA has approved Menveo (Novartis), a new quadrivalent conjugated polysaccharide vaccine, for protection against disease caused by Neisseria meningitidis in people 11-55 years old.
Med Lett Drugs Ther. 2010 Jul 26;52(1343):59-60 |  Show IntroductionHide Introduction

Colonoscopy Preparations

   
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013  (Issue 1408)
The Medical Letter® On Drugs and Therapeutics Published by The Medical Letter, Inc. • 145 ...
Colonoscopy remains the preferred method of colorectal cancer screening. Many patients consider cleansing the bowel in preparation for colonoscopy the most unpleasant part of the procedure, but inadequate bowel preparation significantly lowers the diagnostic yield.
Med Lett Drugs Ther. 2013 Jan 21;55(1408):6-7 |  Show IntroductionHide Introduction

In Brief: Uridine Triacetate (Vistogard) for Fluorouracil Overdose

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 2016  (Issue 1498)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1498) July 4, 2016 Published ...
The FDA has approved the pyrimidine analog uridine triacetate (Vistogard – Wellstat Therapeutics) for emergency treatment of a fluorouracil (5-FU) or capecitabine (Xeloda, and generics) overdose or severe toxicity that occurs within 96 hours following administration of one of these drugs. Fluorouracil is a cytotoxic antimetabolite used to treat breast, colorectal, and other cancers; capecitabine is an oral prodrug of fluorouracil.Uridine triacetate, a prodrug, is deacetylated to uridine after oral administration. Excess circulating uridine is converted into uridine triphosphate, which...
Med Lett Drugs Ther. 2016 Jul 4;58(1498):90 |  Show IntroductionHide Introduction

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
) despite optimal prophylaxis with conventional antiemetic drugs such as palonosetron (Aloxi, and others ...
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-82 |  Show IntroductionHide Introduction

Low Osmolality Contrast Agents

   
The Medical Letter on Drugs and Therapeutics • Sep 22, 1989  (Issue 801)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The US Food and Drug Administration recently approved the marketing of ioversol (Optiray - Mallinckrodt), a new iodinated, low-osmolality, non-ionic X-ray contrast agent. Low-osmolality contrast agents are much more expensive, but they provide as good diagnostic quality as older, high-osmolality contrast media and are claimed to be both better tolerated and safer (Medical Letter, 29:43, 1987).
Med Lett Drugs Ther. 1989 Sep 22;31(801):85-7 |  Show IntroductionHide Introduction

Insulin Aspart, A New Rapid-acting Insulin

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 2001  (Issue 1115)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Insulin aspart (Novolog - Novo Nordisk) is the second rapid-acting insulin analog to be approved by the FDA. The first was insulin lispro (Humalog). Insulin aspart differs from human insulin by substitution of aspartic acid for proline in position 28 on the beta-chain.
Med Lett Drugs Ther. 2001 Oct 15;43(1115):89-90 |  Show IntroductionHide Introduction